Prognosis varies from individual to individual. It ranges from a 95% 5-year survival for localized disease to an 80% 5-year survival for those with liver metastases. The average survival time from the start of octreotide treatment has increased to about 12 years.
Carcinoid syndrome
Anaphylaxis
Carcinosis
Stress ulcer
Portal hypertension
Madarosis
Amyloidosis
Alcohol intolerance